A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an ...

Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency ...

119.391,551,03%) s&p 500 ...

Pfizer PFE announced that the FDA has accepted its supplemental new drug applications (sNDAs) seeking approval of its cancer drugs Braftovi + Mektovi in BRAF V600E-mutant metastatic non-small cell ...

(2023-10-12 | NYSE:PFE) U.S. FDA Approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Stockhouse.com uses cookies on this site. By continuing to use our ...

The combination of Braftovi and Mektovi has been approved for patients with non-small cell lung cancer with the mutation since last year. "All patients with lung cancer should be tested for BRAF ...